Israel · Delayed Price · Currency is ILS · Price in ILA SofWave Medical Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 58% year-over-year in Q4 and 47% for the full year, with ongoing usage fees now 43% of total revenue. Achieved IFRS profitability, strong gross margins, and expanding global footprint, driven by demand for regenerative, non-invasive treatments.
-
Record Q3 revenue and strong profitability were driven by recurring virtual consumable sales and global expansion. Innovative non-invasive technology, high customer satisfaction, and a growing GLP-1 patient segment are fueling demand and supporting a robust financial outlook.
-
Exceptional revenue growth and profitability have been achieved, driven by proprietary technology, recurring revenue, and global expansion. Demand for non-invasive treatments is rising, with strong brand awareness and high provider satisfaction supporting continued growth.
-
Record revenue growth, strong recurring revenue from virtual consumables, and high profitability mark recent performance. Product innovation and regulatory wins, especially in Japan, support global expansion, while GLP-1 trends drive demand for skin tightening and muscle toning.
-
Q3 2025 saw 56% year-over-year revenue growth to $21.1 million, with strong recurring revenue and a 73.7% gross margin. Brand momentum, digital engagement, and regulatory tailwinds are driving adoption, while the company remains resilient amid macroeconomic and competitive challenges.
-
Q2 2025 saw 43% revenue growth year-over-year, record net income, and strong recurring revenue. Gross margin exceeded 75%, with robust cash generation and expanding global presence. Demand for skin tightening and volumization remains high despite macroeconomic headwinds.
-
Aesthetic device sales are accelerating, driven by patented non-invasive ultrasound technology, a recurring revenue model, and strong digital marketing. Recent FDA clearances and global expansion, especially in Asia, support continued growth and profitability.
-
Q1 2025 revenue grew 26% year-over-year to $16.7 million, with recurring pulses up 49%. Brand awareness and demand surged, aided by organic celebrity endorsements and new market entries, notably Japan. Non-GAAP margins reached 76.4%.
-
Aesthetic device demand is surging, fueled by GLP-1 weight loss trends and global expansion, with high ROI and strong brand engagement. The company’s patented technology, recurring revenue model, and proven leadership support rapid growth and profitability.
-
Aesthetic device provider leverages proprietary ultrasound technology and a frictionless business model to drive rapid revenue growth, high margins, and global expansion. Strong brand awareness, digital marketing, and product innovation support continued market share gains and profitability.
Fiscal Year 2024
-
Non-invasive ultrasound technology and a frictionless business model are fueling double-digit growth, high customer ROI, and strong recurring revenue. Global expansion continues, with a focus on brand awareness, product innovation, and margin improvement.